## Stefano Piaserico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2917788/publications.pdf

Version: 2024-02-01

162 papers 4,852 citations

36 h-index 62 g-index

162 all docs 162 docs citations

times ranked

162

4879 citing authors

#	Article	IF	CITATIONS
1	Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opinion on Biological Therapy, 2022, 22, 367-376.	3.1	9
2	Multiparametric analysis of coronary flow in psoriasis using a coronary flow reserve companion. European Journal of Clinical Investigation, 2022, 52, e13711.	3.4	6
3	Whole-Exome Sequencing in 10 Unrelated Patients with Syndromic Hidradenitis Suppurativa: A Preliminary Step for a Genotype-Phenotype Correlation. Dermatology, 2022, 238, 860-869.	2.1	28
4	Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection. Dermatologic Therapy, 2022, 35, e15281.	1.7	2
5	Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opinion on Biological Therapy, 2022, 22, 547-554.	3.1	8
6	Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study. Dermatology, 2022, 238, 897-903.	2.1	5
7	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Italian Journal of Dermatology and Venereology, 2022, 157, 1-78.	0.2	25
8	The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. Journal of Dermatological Treatment, 2022, 33, 2443-2454.	2.2	8
9	Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease. Expert Opinion on Pharmacotherapy, 2022, , 1-12.	1.8	1
10	Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. Journal of Clinical Medicine, 2022, 11, 2801.	2.4	6
11	Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?. Frontiers in Immunology, 2022, 13, .	4.8	10
12	Clinicopathological features, <scp>MCPyV</scp> status and outcomes of Merkel cell carcinoma in <scp>solidâ€organ</scp> transplant recipients: a retrospective, multicentre cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1991-2001.	2.4	8
13	Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated—A Systematic Review. BioMed Research International, 2022, 2022, 1-12.	1.9	7
14	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clinical Rheumatology, 2021, 40, 2251-2262.	2.2	10
15	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€"insights from a global registryâ€"based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	2.9	136
16	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 2021, 21, 271-277.	3.1	40
17	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: AÂNorthern Italy experience. Journal of Allergy and Clinical Immunology, 2021, 147, 558-560.e1.	2.9	44
18	Correspondence on â€Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'. Annals of the Rheumatic Diseases, 2021, 80, e79-e79.	0.9	9

#	Article	IF	CITATIONS
19	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	1.3	5
20	Skin cancers in Italian lung transplant recipients: Incidence and risk factors analysis. Dermatologic Therapy, 2021, 34, e14749.	1.7	0
21	Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. European Journal of Dermatology, 2021, 31, 3-16.	0.6	10
22	Insights into Sarsâ€CoVâ€2 vaccination in patients with chronic plaque psoriasis on systemic treatments. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e361-e362.	2.4	9
23	Is SARSâ€CoVâ€2 screening test indicated for psoriasis patients candidate to biologic therapy?. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e355-e357.	2.4	2
24	Drug Survival of IL-12/23, IL-17 and IL-23 InhibitorsÂfor Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.	6.7	65
25	Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. Dermatology and Therapy, 2021, 11, 695-705.	3.0	17
26	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. BioDrugs, 2021, 35, 469-471.	4.6	7
27	Fiveâ€year efficacy and safety of tildrakizumab in patients with moderateâ€toâ€severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. British Journal of Dermatology, 2021, 185, 323-334.	1.5	55
28	Sequential treatment with calcitriol and methyl aminolevulinate-daylight photodynamic therapy for patients with multiple actinic keratoses of the upper extremities. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102325.	2.6	8
29	Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. Dermatology and Therapy, 2021, 11, 1333-1343.	3.0	17
30	Impact of the COVIDâ€19 pandemic on melanoma diagnosis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e714-e715.	2.4	20
31	Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. Journal of Investigative Dermatology, 2021, , .	0.7	9
32	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy, 2021, 11, 235-252.	3.0	34
33	Diagnosis and management of cutaneous and anogenital lichen sclerosus: recommendations from the Italian Society of Dermatology (SIDeMaST). Italian Journal of Dermatology and Venereology, 2021, 156, 519-533.	0.2	3
34	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis: Targets and Therapy, 2021, Volume 11, 151-168.	2,2	10
35	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clinical and Experimental Rheumatology, 2021, 39, 1099-1107.	0.8	2
36	Perianal ulcer caused by Serratia marcescens. Italian Journal of Dermatology and Venereology, 2021, 156, 256-257.	0.2	0

#	Article	IF	Citations
37	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment, 2020, 31, 476-483.	2.2	23
38	Zoon Balanitis: misdiagnosis or missed diagnosis?. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e117-e118.	2.4	0
39	European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications – field cancerization, photorejuvenation and inflammatory/infective dermatoses. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 17-29.	2.4	78
40	Management of biological therapies for chronic plaque psoriasis during COVIDâ€19 emergency in Italy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e770-e772.	2.4	31
41	Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. American Journal of Clinical Dermatology, 2020, 21, 749-751.	6.7	27
42	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a realâ€world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	2.4	6
43	Switching from one infliximab biosimilar (CTâ€P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. British Journal of Dermatology, 2020, 183, 397-398.	1.5	17
44	Consensus on the place in therapy of TNF $\hat{a}\in\hat{I}_{\pm}$ inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472.	2.4	6
45	Efficacy of topical photodynamic therapy in the treatment of erythroplasia of Queyrat. Dermatology Reports, 2020, 12, 8566.	0.8	2
46	REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19. Journal of Infection, 2020, 81, e37-e38.	3.3	2
47	Cutaneous manifestations of SARSâ€CoVâ€2 infection: a clinical update. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2499-2504.	2.4	96
48	Italian expert consensus paper on the management of patients with actinic keratoses. Dermatologic Therapy, 2020, 33, e13992.	1.7	12
49	The impact of the <scp>COVID</scp> â€19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. British Journal of Dermatology, 2020, 183, 373-374.	1.5	104
50	SARSâ€CoVâ€2 infection in a psoriatic patient treated with ILâ€23 inhibitor. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e254-e255.	2.4	54
51	Dermatologists and SARSâ€CoVâ€2: the impact of the pandemic on daily practice. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1196-1201.	2.4	85
52	TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 591-598.	3.0	18
53	Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives. Current Vascular Pharmacology, 2020, 18, 592-609.	1.7	6
54	Psoriasis and Dementia: A Cross-sectional Study of 121,801 Patients. Acta Dermato-Venereologica, 2020, 100, adv00250.	1.3	10

#	Article	IF	Citations
55	SATO412â€ACCURACY OF AN INSTRUMENT FOR SCREENING PSORIATIC ARTHRITIS AMONG PSORIATIC PATIENT RESULTS FROM THE MULTICENTRE ITALIAN STUDY HERACLES (SCREENING STRATEGIES FOR) Tj ETQq1 1 0.78431 of the Rheumatic Diseases, 2020, 79, 1158.2-1159.	TS: .4.rgBT /(	Overlock 10
56	A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 392-399.	0.8	4
57	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clinical Rheumatology, 2019, 38, 2843-2850.	2.2	39
58	P377Arrhythmogenic cardiomyopathy in epidermolysis bullosa: are desmosomes at fault for both?. European Heart Journal Cardiovascular Imaging, 2019, 20, .	1.2	0
59	Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis, 2019, 289, 57-63.	0.8	23
60	Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report. Experimental and Therapeutic Medicine, 2019, 18, 2746-2748.	1.8	1
61	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. American Journal of Clinical Dermatology, 2019, 20, 829-845.	6.7	28
62	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 273-275.	1.2	39
63	Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. British Journal of Dermatology, 2019, 182, 175-179.	1.5	3
64	Secukinumab shows high efficacy irrespective of <i>HLAâ€Cw6</i> status in patients with moderateâ€toâ€severe plaqueâ€type psoriasis: results from extension phase of the SUPREME study. British Journal of Dermatology, 2019, 181, 413-414.	1.5	21
65	A case–control study of risk factors associated with Zoon balanitis in men. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1591-1594.	2.4	7
66	Pruritus characteristics in a large Italian cohort of psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1316-1324.	2.4	46
67	European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen's disease and basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2225-2238.	2.4	118
68	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. British Journal of Dermatology, 2019, 180, 1547-1548.	1.5	30
69	Accuracy of dermoscopy in distinguishing erythroplasia of Queyrat from common forms of chronic balanitis: results from a multicentric observational study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 966-972.	2.4	23
70	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 376-377.	0.8	3
71	Italian Guidelines in diagnosis and treatment of alopecia areata. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 609-623.	0.8	39
72	Eczematous, Pruritic, Brownish Plaque of the Nipple and Areola: A Quiz. Acta Dermato-Venereologica, 2019, 99, 1317-1318.	1.3	2

#	Article	IF	Citations
73	A Case of Secondary Osteoma Cutis Associated with Lichen Planopilaris. Acta Dermato-Venereologica, 2019, 99, 1190-1191.	1.3	1
74	Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with non-Hodgkin lymphoma: a possible indication for prophylaxis. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 736-737.	0.8	0
75	Comorbidities in Autoimmune Skin Diseases. JAMA Dermatology, 2018, 154, 264.	4.1	O
76	Simulating the life course of psoriasis patients: the interplay between therapy intervention and marital status. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 62-67.	2.4	4
77	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 515-528.	2.4	15
78	Central Obesity in Children with Psoriasis. Acta Dermato-Venereologica, 2018, 98, 282-283.	1.3	20
79	How to improve adherence to treatment in patients with mild-to-moderate psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 692-697.	0.8	7
80	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1853-1859.	2.4	27
81	Italian guidelines on the systemic treatments of moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790.	2.4	140
82	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. American Journal of Clinical Dermatology, 2017, 18, 253-271.	6.7	49
83	The heart of the problem. British Journal of Dermatology, 2017, 176, 849-850.	1.5	0
84	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. British Journal of Dermatology, 2017, 177, e325-e326.	1.5	19
85	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Reply to Dr. Ricceri letter. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e486-e487.	2.4	2
86	Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatologic Therapy, 2017, 30, e12503.	1.7	10
87	Painful skin lesions and squamous cell carcinoma predict overall mortality risk in organ transplant recipients: a cohort study. British Journal of Dermatology, 2017, 176, 1179-1186.	1.5	5
88	Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. European Journal of Dermatology, 2017, 27, 599-608.	0.6	30
89	Brownish-grey, Papular Scaling Rash on the Trunk and Lower Limbs: A Quiz. Acta Dermato-Venereologica, 2017, 97, 769-771.	1.3	1
90	Atrophic pityriasis versicolor occurring in a patient with Sjögren's syndrome. BMJ Case Reports, 2017, 2017, bcr2016218108.	0.5	5

#	Article	IF	Citations
91	Symmetrical, Hypopigmented Papules and Plaques on the Palms Induced by Contact with Water: A Quiz. Acta Dermato-Venereologica, 2016, 96, 575-576.	1.3	2
92	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. Acta Dermato-Venereologica, 2016, 96, 251-252.	1.3	21
93	Italian expert consensus for the management of actinic keratosis in immunocompetent patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1077-1084.	2.4	41
94	Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis, 2016, 251, 25-30.	0.8	47
95	Assessing the Impact of Atopic Dermatitis on the Patients' Parents with the Visual Instrument †Caregiver-PRISM'. Dermatology, 2016, 232, 490-495.	2.1	7
96	TLR7 Gln11Leu single nucleotide polymorphism and response to treatment with imiquimod in patients with basal cell carcinoma: a pilot study. Pharmacogenomics, 2015, 16, 1913-1917.	1.3	10
97	Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1718-1723.	2.4	92
98	Daylight photodynamic therapy with methyl-aminolevulinate for the treatment of actinic cheilitis. Dermatologic Therapy, 2015, 28, 355-368.	1.7	21
99	Polypodium Leucotomos Supplementation in the Treatment of Scalp Actinic Keratosis. Dermatologic Surgery, 2015, 41, 898-902.	0.8	22
100	Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis. Journal of Dermatological Science, 2015, 78, 149-151.	1.9	21
101	European Dermatology Forum Guidelines on topical photodynamic therapy. European Journal of Dermatology, 2015, 25, 296-311.	0.6	125
102	Autochthonous Hookworm-Related Cutaneous Larva Migrans Disease in Northeastern Italy: A Case Report. Journal of Parasitology, 2015, 101, 488-489.	0.7	7
103	<scp>PSOCUBE</scp> , a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidenceâ€based algorithm. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1310-1317.	2.4	8
104	Efficacy of Biofeedback and Cognitive-behavioural Therapy in Psoriatic PatientsA Single-blind, Randomized and Controlled Study with Added Narrow-band Ultraviolet B Therapy. Acta Dermato-Venereologica, 2014, 96, 91-5.	1.3	15
105	Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. Acta Dermato-Venereologica, 2014, 96, 96-101.	1.3	4
106	Psoriasis – The Life Course Approach. Acta Dermato-Venereologica, 2014, 96, 102-8.	1.3	4
107	Quality of Life Assessment of Patients with Scalp Dermatitis Using the Italian Version of the Scalpdex. Acta Dermato-Venereologica, 2014, 94, 411-414.	1.3	25
108	Rejection-mediated Regression of Melanocytic Naevi in an Immunosuppressed Organ Transplant Recipient. Acta Dermato-Venereologica, 2014, 94, 733-734.	1.3	0

#	Article	IF	Citations
109	Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients. Acta Dermato-Venereologica, 2014, 94, 293-297.	1.3	71
110	Pain Identifies Squamous Cell Carcinoma in Organ Transplant Recipients: The SCOPE-ITSCC PAIN Study. American Journal of Transplantation, 2014, 14, 668-676.	4.7	16
111	Effects of TNF-Alpha Inhibitors on Circulating Th17 Cells in Patients Affected by Severe Psoriasis. Drug Development Research, 2014, 75, S73-S76.	2.9	14
112	Consensus recommendations for the treatment of basal cell carcinomas in <scp>G</scp> orlin syndrome with topical methylaminolaevulinateâ€photodynamic therapy. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 626-632.	2.4	44
113	Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry. Journal of the American Academy of Dermatology, 2014, 70, 257-262.e3.	1.2	54
114	Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment. Drug Development Research, 2014, 75, S24-S26.	2.9	19
115	Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis. European Journal of Dermatology, 2014, 24, 133-135.	0.6	12
116	Kaposi's sarcoma and other rare skin cancers in organ transplant patients. Giornale Italiano Di Dermatologia E Venereologia, 2014, 149, 395-400.	0.8	1
117	Cutaneous viral infections in organ transplant patients. Giornale Italiano Di Dermatologia E Venereologia, 2014, 149, 409-15.	0.8	15
118	Photodynamic therapy for actinic keratosis in organ transplant patients. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 57-66.	2.4	50
119	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. Journal of Dermatological Treatment, 2013, 24, 305-311.	2.2	28
120	Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: A pilot study. Acta Histochemica, 2013, 115, 767-769.	1.8	1
121	Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?. Expert Opinion on Biological Therapy, 2013, 13, 1673-1682.	3.1	56
122	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. British Journal of Dermatology, 2013, 168, 1124-1127.	1.5	67
123	Cumulative Life Course Impairment in Melanoma and Nonmelanoma Skin Cancer. Current Problems in Dermatology, 2013, 44, 118-124.	0.7	3
124	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. Acta Dermato-Venereologica, 2012, 92, 411-415.	1.3	34
125	Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. Immunopharmacology and Immunotoxicology, 2012, 34, 901-906.	2.4	3
126	Impaired coronary flow reserve in young patients affected by severe psoriasis. Atherosclerosis, 2012, 221, 113-117.	0.8	65

#	Article	IF	Citations
127	Psoriasis segmentation through chromatic regions and Geometric Active Contours., 2012, 2012, 5388-91.		9
128	Psodisk, a new visual method for assessing the burden of psoriasis on patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1163-1166.	2.4	26
129	Bullous Scabies Simulating Pemphigoid. Journal of Cutaneous Medicine and Surgery, 2011, 15, 55-57.	1.2	10
130	Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study. Clinical Transplantation, 2010, 24, 328-333.	1.6	12
131	<i>PTCH1</i> gene haplotype association with basal cell carcinoma after transplantation. British Journal of Dermatology, 2010, 163, 364-370.	1.5	18
132	Melanoma and Immunosuppression. Dermatology, 2009, 218, 88-88.	2.1	11
133	Generalized Granuloma Annulare Treated with Methylaminolevulinate Photodynamic Therapy. Dermatology, 2009, 218, 282-284.	2.1	21
134	Acne Keloidalis of the Scalp in a Renal Transplant Patient Treated with Cyclosporine. Acta Dermato-Venereologica, 2009, 89, 312-313.	1.3	8
135	Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma in a Heart Transplant Patient: Case Report and Literature Review. Acta Dermato-Venereologica, 2009, 89, 74-77.	1.3	19
136	Kobner phenomenon in psoriasis induced by Mantoux test. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1103-1105.	2.4	7
137	Immunosuppression and melanocyte proliferation. Melanoma Research, 2009, 19, 63-68.	1.2	61
138	Squamous Cell Carcinoma. Cancer Treatment and Research, 2009, 146, 241-261.	0.5	7
139	Melanoma in Organ Transplant Recipients: Clinicopathological Features and Outcome in 100 Cases. American Journal of Transplantation, 2008, 8, 1891-1900.	4.7	107
140	Topical Photodynamic Therapy of Actinic Keratosis in Renal Transplant Recipients. Transplantation Proceedings, 2007, 39, 1847-1850.	0.6	75
141	Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. British Journal of Dermatology, 2007, 157, 49-57.	1.5	35
142	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study. British Journal of Dermatology, 2007, 157, 68-73.	1.5	543
143	Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. Journal of the American Academy of Dermatology, 2006, 54, 338-340.	1.2	30
144	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Experimental Dermatology, 2006, 15, 958-965.	2.9	29

#	Article	IF	Citations
145	Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. European Journal of Dermatology, 2006, 16, 553-7.	0.6	30
146	Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn??s disease. Melanoma Research, 2005, 15, 223-224.	1.2	18
147	C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transplant International, 2005, 18, 116-124.	1.6	27
148	Abnormal total ejection isovolume index as early noninvasive marker of chronic rejection in heart transplantation*. Transplant International, 2005, 18, 303-308.	1.6	7
149	Skin disorders in patients transplanted in childhood. Transplant International, 2005, 18, 360-365.	1.6	17
150	Immunosuppressive Level and Other Risk Factors for Basal Cell Carcinoma and Squamous Cell Carcinoma in Heart Transplant Recipients. Archives of Dermatology, 2004, 140, 1079-85.	1.4	105
151	Posttraumatic Port-Wine Stain in a 4-Year-Old Girl: Fegeler Syndrome. Pediatric Dermatology, 2004, 21, 131-133.	0.9	18
152	Immune and Nonimmune Predictors of Cardiac Allograft Vasculopathy Onset and Severity: Multivariate Risk Factor Analysis and Role of Immunosuppression. American Journal of Transplantation, 2004, 4, 962-970.	4.7	129
153	Allergic contact sensitivity in elderly patients. Aging Clinical and Experimental Research, 2004, 16, 221-225.	2.9	37
154	Eruptive melanocytic nevi in patients with renal allografts: Report of 10 cases with dermoscopic findings. Journal of the American Academy of Dermatology, 2003, 49, 1020-1022.	1.2	65
155	Monoclonal gammopathy in heart transplantation: risk factor analysis and relevance of immunosuppressive load. Transplantation Proceedings, 2001, 33, 1583-1584.	0.6	14
156	High rejection score in the first year and risk of skin cancer in heart transplantation. Transplantation Proceedings, 2001, 33, 1608-1609.	0.6	2
157	De novo noncutaneous malignancies in heart transplantation: a single-centre 15-year experience and risk factor analysis. Transplantation Proceedings, 2001, 33, 3658-3659.	0.6	6
158	PIBI(D)S: clinical and molecular characterization of a new case. Journal of the European Academy of Dermatology and Venereology, 2001, 15, 65-69.	2.4	9
159	Diaminodiphenylmethane (DDM): frequency of sensitization, clinical relevance and concomitant positive reactions. Contact Dermatitis, 2001, 44, 283-288.	1.4	18
160	Skin Cancer in Heart Transplant Recipients: Risk Factor Analysis and Relevance of Immunosuppressive Therapy. Circulation, 2000, 102, III-222-III-227.	1.6	99
161	RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY. Transplantation, 2000, 70, 1479-1484.	1.0	104
162	Skin cancer in heart transplant recipients: frequency and risk factor analysis. Journal of Heart and Lung Transplantation, 2000, 19, 249-255.	0.6	121